{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:39Z","timestamp":1775695719435,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.102971","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T02:37:53Z","timestamp":1620095873000},"page":"102971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immune reconstitution therapy in NMOSD"],"prefix":"10.1016","volume":"52","author":[{"given":"Staley A.","family":"Brod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt 9","key":"10.1016\/j.msard.2021.102971_bib0038","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1093\/brain\/awt182","article-title":"Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis","volume":"136","author":"Abrahamsson","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.102971_bib0009","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2017.11.022","article-title":"Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica","volume":"384","author":"Ajmera","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2021.102971_bib0015","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrn1252","article-title":"The molecular basis of water transport in the brain","volume":"4","author":"Amiry-Moghaddam","year":"2003","journal-title":"Nature reviews Neuroscience"},{"issue":"7","key":"10.1016\/j.msard.2021.102971_bib0048","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jocn.2015.02.007","article-title":"Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant","volume":"22","author":"Aouad","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2021.102971_bib0037","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clim.2016.06.005","article-title":"Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation","volume":"169","author":"Arruda","year":"2016","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2021.102971_bib0032","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13311-012-0162-5","article-title":"Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned","volume":"10","author":"Atkins","year":"2013","journal-title":"Neurotherapeutics"},{"issue":"10044","key":"10.1016\/j.msard.2021.102971_bib0041","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0014","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0304-3940(00)01364-1","article-title":"Presence of aquaporin-4 and muscarinic receptors in astrocytes and ependymal cells in rat brain: a clue to a common function?","volume":"292","author":"Badaut","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.msard.2021.102971_bib0011","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102971_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.10.1109","article-title":"Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD)","author":"Bennett","year":"2019","journal-title":"J. Neuro. Sci."},{"key":"10.1016\/j.msard.2021.102971_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102971_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101967","article-title":"In MS: immunosuppression is passe","volume":"40","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0036","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/imm.12129","article-title":"T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis","volume":"140","author":"Burman","year":"2013","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.msard.2021.102971_bib0059","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0043","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.msard.2021.102971_bib0047","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102971_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102404","article-title":"Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America","volume":"45","author":"Burt","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0049","article-title":"Plegia to walking: AHSCBMT in severe NMOSD relapse","volume":"2","author":"Carlisle","year":"2020","journal-title":"J. Neurol. Neurosurg. Psych."},{"issue":"10","key":"10.1016\/j.msard.2021.102971_bib0051","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/acn3.50843","article-title":"T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica","volume":"6","author":"Ceglie","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10206","key":"10.1016\/j.msard.2021.102971_bib0020","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102971_bib0021","series-title":"Proceedings of the 5th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum","article-title":"The N-MOmentum study \u2013 a randomized, placebo-controlled, double-blind trial of inebilizumab for neuromyelitis optica spectrum disorder: randomized controlled period and open-label extension results","author":"Cree","year":"2020"},{"issue":"3","key":"10.1016\/j.msard.2021.102971_bib0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102971_bib0040","doi-asserted-by":"crossref","unstructured":"Delemarre EM, van den Broek T, Mijnheer G, et\u00a0al. Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. 1392-1397. 2016;127(1):91-101.","DOI":"10.1182\/blood-2015-06-649145"},{"issue":"5","key":"10.1016\/j.msard.2021.102971_bib0013","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102971_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010012","article-title":"Ocrelizumab depletes CD20(+) T cells in multiple sclerosis patients","volume":"8","author":"Gingele","year":"2018","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.msard.2021.102971_bib0056","first-page":"543","article-title":"Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis","volume":"15","author":"Goldberg","year":"2009","journal-title":"J. Manag. Care Pharm."},{"issue":"3","key":"10.1016\/j.msard.2021.102971_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24079","article-title":"Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica","volume":"75","author":"Greco","year":"2014","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0046","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102971_bib0008","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/B978-0-444-63432-0.00021-9","article-title":"Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders","volume":"133","author":"Hinson","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.msard.2021.102971_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflamm."},{"issue":"14","key":"10.1016\/j.msard.2021.102971_bib0005","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.102971_bib0034","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/cei.12985","article-title":"Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation","volume":"189","author":"Karnell","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"Pt 6","key":"10.1016\/j.msard.2021.102971_bib0007","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2021.102971_bib0058","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3111\/13696998.2012.693553","article-title":"Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States","volume":"15","author":"Lee","year":"2012","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.msard.2021.102971_bib0031","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(08)70138-8","article-title":"Autologous haematopoietic stem-cell transplantation in multiple sclerosis","volume":"7","author":"Mancardi","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102971_bib0054","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2018.00410","article-title":"Regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant","volume":"9","author":"Massey","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2021.102971_bib0010","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102971_bib0002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","article-title":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.","volume":"28","author":"Mealy","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2021.102971_bib0029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"3","key":"10.1016\/j.msard.2021.102971_bib0027","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2021.102971_bib0033","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.msard.2021.102971_bib0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2021.102971_bib0042","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.102971_bib0057","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/WNL.0b013e3182270402","article-title":"Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study","volume":"77","author":"Noyes","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.102971_bib0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3111\/13696998.2011.602444","article-title":"Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis","volume":"14","author":"O'Day","year":"2011","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2021.102971_bib0028","unstructured":"OCREVUS PI- https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761053lbl.pdf."},{"issue":"2","key":"10.1016\/j.msard.2021.102971_bib0025","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.msard.2021.102971_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2021.102971_bib0017","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.102971_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102971_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"22","key":"10.1016\/j.msard.2021.102971_bib0044","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"issue":"Pt 5","key":"10.1016\/j.msard.2021.102971_bib0039","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awh117","article-title":"Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis","volume":"127","author":"Sun","year":"2004","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2021.102971_bib0052","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/bmt.2009.305","article-title":"Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis","volume":"45","author":"Tappenden","year":"2010","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"10.1016\/j.msard.2021.102971_bib0016","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14728222.2017.1398236","article-title":"The aquaporin-4 water channel as a potential drug target in neurological disorders","volume":"21","author":"Verkman","year":"2017","journal-title":"Exp. Opin. Ther. Targets"},{"issue":"5","key":"10.1016\/j.msard.2021.102971_bib0003","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2021.102971_bib0004","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"22","key":"10.1016\/j.msard.2021.102971_bib0022","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:56Z","timestamp":1761900956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":59,"alternative-id":["S2211034821002388"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102971","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune reconstitution therapy in NMOSD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102971"}}